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Analogs of 6-mercaptopurine have been found to en 
hance the detoxification of various electrophilic toxi 
cants in vivo, while having minimal cytotoxicity them 
selves. This property allows such compounds to act as 
scavengers for electrophilic toxicants, thereby prevent 
ing the cellular damage caused by such toxic agents. 
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CHEMOPREVENTION OF ELECTROPHILIC 
DAMAGE BY MERCAPTOPURINE ANALOGS 
The U.S. governmentr may own certain rights in this 
invention pursuant to NIEHS grant No ES03602. 
This application is a continuation-in-part of U.S. Ser. 
No. 262,880, filed on Oct. 26, 1988, now abandoned. 
BACKGROUND OF THE INVENTION 
The present invention relates to a method of prevent 
ing cellular damage caused by electrophilic toxic, carci 
nogenic, or mutagenic agents. 
It is well known that some chemical compounds are 
carcinogenic. Further, it is widely accepted that most 
chemical carcinogens either are strongly electrophilic 
or are metabolized by cellular enzymes to electrophilic 
derivatives. These electrophilic "ultimate' carcinogens 
react with nucleophilic groups in cellular macromole 
cules, and it is the macromolecular damage which leads 
to carcinogenesis, mutagenesis and toxicity. Classes of 
carcinogens which appear to act in this way include 
aromatic amines, the polycyclic aromatic hydrocar 
bons, nitrosamines and nitrosamides, and nitrogen mus 
tards. In addition, some therapeutic toxicants, e.g. those 
used in cancer chemotherapy, may act in this way or 
may produce undesirable side effects through this 
mechanism. One strategy for intervention in these pro 
cesses would be to provide a chemical scavenger for the 
toxic electrophiles, which would prevent macromolec 
ular damage by prior reaction with the ultimate carcino 
gen. 
This strategy has achieved limited success with two 
sets of compounds. The first set includes several pheno 
lic plant compounds, exemplified by ellagic acid. These 
compounds scavenge electrophiles well in vitro, but 
have limited ability to block polycyclic aromatic hydro 
carbon-included carcinogenesis in vivo. This is presum 
ably due to problems with the pharmacokinetics of the 
compounds. A second set is the dithio-thiones. These 
were designed to be limited to direct acting, gut carcin 
ogens since the chemopreventive compounds are not 
taken up by cells. This limits problems due to side ef 
fects, but also drastically restricts the range of carcino 
gens and target tissues to which the strategy is applica 
ble. 
In general, the limitations to the success of the nu 
cleophilic scavenging strategy of chemoprevention are: 
1) the production of undesirable side effects; 2) inability 
to achieve therapeutic concentrations intracellularly; 
and 3) inability to colocalize with the often hydropho 
bic carcinogens within subcellular compartments. 
It is clear that the major xenobiotic metabolizing 
system of mammalian cells the cytochrome P450 sys 
tem, is microsonal in origin. For carcinogens such as 
the polycyclic aromatic hydrocarbons, which require 
metabolic activation, this is thought to lead to preferen 
tial localization of the metabolites in cellular mem 
branes. Indeed, tests using a highly reactive, ultimate 
carcinogen derived from benzo(a)pyrene have shown 
that a pool of membrane-localized electrophile remains 
active in DNA binding for relatively long periods of 
time. Similar conclusions have been reached for the 
same electrophile in two-stage mouse skin carcinogene 
sis. Therefore, a potential chemopreventive agent 












1. The agent should facilely detoxify electrophilic 
carcinogens, either by forming a covalent adduct or by 
catalysing other detoxification reactions or both; 
2. The agent should be a substrate for an endogenous 
cellular transport system to ensure that it quickly 
reaches and maintains therapeutic intracellular concen 
trations; 
3. The agent should have enough hydrophobic char 
acter to allow it to colocalize with those carcinogens 
which are hydrophobic; and 
4. Toxicity should be minimal. 
The compound 6-mercaptopurine (6-MP) has been 
found to satisfy the first three criteria. In addition, it is 
able to inhibit several biological activities (DNA dam 
age, mutagenesis) of an ultimate carcinogen in Chinese 
hamster ovary cells. However, 6-MP is used as a cyto 
toxic agent in the treatment of childhood leukemia and 
therefore fails to meet the fourth criterion. 
Therefore, a need exists for chemopreventive agents 
which can satisfy all these criteria. 
SUMMARY OF THE INVENTION 
A method in accordance with the present invention 
of detoxifying electrophilic toxicants includes the step 
of administering to an animal an effective amount of a 
compound having a low level of cytotoxicity, said com 
pound being a substrate for an endogenous cellular 
transport system, said compound being selected from 
the group consisting of compounds having the formula: 
Xl 
N S) O O 
x-N N N 
and compounds having the formula: 
Xl 
O TO N 
-N / N N 
X3 
One of X, X2, and X is a thiol having from 0-10 car 
bons, while another one of X1, X2, and X is selected 
from the group consisting of halogens, thiols having 
from 0-10 carbons, aliphatic and aromatic hydrocar 
bons having from 1-18 carbons, and OR, where R is 
selected from the group consisting of hydrogen and 
aliphatic and aromatic hydrocarbons having from 1-18 
carbons. The remaining one of X1,X2, and X3 is selected 
from the group consisting of H, halogens, thiols having 
0-10 carbons, aliphatic and aromatic hydrocarbons 
having 1-18 carbons, and OR2, where R2 is selected 
from the group consisting of H and aliphatic and aro 
matic hydrocarbons having 1-18 carbons. 
In this patent, "aliphatic and aromatic hydrocarbons' 
is used to mean both unsubstituted and substituted hy 
drocarbons. "Toxicants' is used to mean agents which 
have toxic, carcinogenic, and/or mutagenic effects. 
Further, "detoxifying' is used to mean substantially 
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reducing the toxic, carcinogenic, or mutagenic proper 
ties of a chemical agent. 
In the embodiment of the present invention described 
above, the thiol groups preferably have from 0-4 car 
bons, and the aliphatic and aromatic hydrocarbons pref. 
erably have from 1-6 carbons. 
In another embodiment of the present invention, the 
method makes use of chemopreventive agents having 
one of the following two formulas: 
x4 x4 
O6) O6 N x-N. -N1/ 
X6 k 
In this embodiment, X is a thiol having 0-10 carbons, 
and X5 and X6 are each independently selected from the 
group consisting of H, halogens, thiols having 0-10 
carbons, aliphatic and aromatic hydrocarbons having 
1-18 carbons, and OR, where R is selected from the 
group consisting of H and aliphatic and aromatic hydro 
carbons having 1-18 carbons. Only one of Xand X6 can 
be H. X* is preferably SH, and the thiol groups from 
which X and X6 can be selected preferably have 0-4 
carbons, while the aliphatic and aromatic hydrocarbons 
preferably have 1-6 carbons. 
In another embodiment of the present invention, X is 
a thiol having 0-4 carbons, X5 is selected from the 
group consisting of H, thiols having 0-4 carbons, hy 
droxyl, and alkyl having 1-6 carbons. X6 is selected 
from the group consisting of H, SH, and alkyls having 
1-6 carbons. Again, only one of X5 and X6 can be H. In 
a preferred form of this embodiment, X* is SH, X5 is 
selected from the group consisting of H, SH, hydroxyl, 
and methyl, and X is selected from the group consisting 
of H, SH, and methyl. 
The present invention provides a method of detoxify 
ing electrophilic toxicants in vivo in animals, such as 
mammals. Specific examples of animals with respect to 
which the present invention should be useful include 
humans, and various avian species. In a particular em 
bodiment of the invention, the method can be used to 
detoxify in vivo mixtures of toxicants in which polycy 
clic aromatic hydrocarbons are a major component. 
The method makes use of chemopreventive agents 
which contain a thiol group, and therefore can facilely 
detoxify electrophilic carcinogens, either by forming a 
covalent adduct, or by catalyzing other detoxification 
reactions, or both. The agents are substrates for endoge 
nous cellular transport systems, which insures that they 
will quickly reach and maintain therapeutic intracellu 
lar concentrations. Further, the chemopreventive 
agents have enough hydrophobic character to allow 
them to co-localize within subcellular compartments 
with those carcinogens which are hydrophobic. Fi 
nally, but quite importantly, the chemopreventive 
agents used in the method of the present invention are 
not incorporated into cellular nucleic acids at levels 
sufficient to produce significant toxicity. Thus, the 
method claimed in this patent produces minimal unde 
sirable side effects. 
Because the chemopreventive agents of the present 
invention are sufficiently similar to purine, they take 
advantage of the endogenous purine transporter to rap 












trations of the chemopreventive agents. Since the toxic 
ity of 6-mercaptopurine (6-MP) is known to result from 
its incorporation into cellular nucelotide pools and nu 
cleic acids, and since the facile reaction of 6-MP with a 
model electrophile is mediated through the thiol moiety 
at carbon 6, it is believed that analogs of 6-MP which 
contain the reactive thiol but are unable to enter nucleo 
tide pools due to their chemical substituents (e.g. at the 
9 position) should satisfy all four criteria outlined 
above. Thus, methods in accordance with the present 
invention have the potential to prevent the biological 
damage produced by electrophilic carcinogens and 
other toxicants. 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIG. 1 is a graph showing the effect of dithiopurine 
on tumorigenesis in mice. 
FIG. 2 is a graph showing the effect of thiopurinol on 
tumorigenesis in mice. 
DETALED DESCRIPTION OF SPECIFIC 
EMBODIMENTS 
The electrophilic toxicants which the methods of the 
present invention can detoxify are believed to include 
those listed below. The list includes 7 classes of com 
pounds, with one or two examples of each, which are 
known to cause cancer in experimental animals and are 
thought to be important in human carcinogenesis. Each 
of the classes of compounds is thought to produce the 
DNA damage which initiates carcinogenesis by way of 
one or more electrophilic intermediates. Because of the 
importance of these electrophilic intermediates, it is 
believed that nucleophilic scavenging agents in accor 
dance with the present invention will be effective 
against many or all of these toxicants. The list is meant 
to be illustrative only, not exhaustive. In addition, it is 
likely that there exist other electrophilic toxicants not 
on the list (e.g. other components of tobacco smoke), 
possibly undescribed, which will also be effectively 
scavenged by the mercaptopurine analogs. 
1. Polynuclear Aromatic Hydrocarbons 
Benzo(a)pyrene 
3-methylcholanthrene 






4. Alkylating Agents 
Dimethyl sulfate 
Ethylnitrosourea 
5. Natural Products 
Aflatoxin B1 
Safrole 
6. Tobacco-specific Carcinogens 
4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) 
7. Chenotherapy Agents 
Nitrogen mustards 
Cisplatin 
At least some of the compounds described in this 
patent are available from Aldrich Chemical Co. (Mil 
waukee, Wis.) or Sigma Chemical Co. (St. Louis, Mo.). 
Further, compounds in accordance with the present 
invention can be synthesized by the procedures de 
scribed in Robins, J. Am. Chem. Soc. 78:784 (1956); 
Beaman, J. Am. Chem. Soc. 76:5633 (1954) and Fischer, 
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Ber. 31:431 (1898), all of which are incorporated herein 
by reference. 
For example, as described by Beaman, 2-hydroxy-6- 
MP can be prepared by adding 15.1 g of xanthine and 81 
g of phosphorous pentasulfide to 1350 ml of stirred, dry 
reagent pyridine. After stirring and refluxing for 3.5 
hours, the hot solution was decanted from 0.55 g of 
solid into 8 1 of water plus ice. This formed a solid 
which remained insoluble on addition of dilute NaOH 
solution and was discarded. The filtrate from this solid 
made acid with acetic acid, was boiled down to about 
4.51 and cooled, forming 11.2 g of an orange-brown 
solid. Trituration with acetone removed much of the 
dark color. The remaining solid was dissolved in a solu 
tion of 7.5 g of NaOH in about 650 ml of water, the 
solution treated with charcoal and filtered, and the 
filtrate heated to boiling and made acid with acetic acid. 
A light yellow solid formed which weighed 8.06 g 
(50%) based on the weight of xanthine which dissolved. 
Likewise, as described by Beaman, 2,6-dithiopurine 
can be prepared by adding 2-thio-6-hydroxypurine (50 
g) and 200 g of phosphorus pentasulfide to 1750 ml of 
stirred, dry reagent pyridine. The mixture was refluxed 
for 1.5 hours and the resulting red-black solution al 
lowed to cool about 10 minutes with stirring. It was 
then poured with stirring into a solution of 663 g of 
NaOH in 5 l of water plus ice. The two layers which 
formed were thoroughly shaken in a separatory funnel 
and separated. The pyridine layer was washed with a 
cold solution of 70 g of NaOH in 500 ml of water, and 
this was combined with the main aqueous layer which 
was then acidified with 1200 ml of glacial acetic acid. 
The mixture was cooled in ice, and the brown solid 
which formed was collected and washed with water. 
After air drying it weighed 44 g (80% crude yield). For 
purification the crude material was dissolved in a solu 
tion of 22 g of NaOH in about 4 1 of water and the 
solution filtered from a little insoluble solid. The filtrate 
was treated with charcoal, filtered, and the boiling fil 
trate acidified with acetic acid. The solid which formed 
on cooling was purified again in the same way to give 
30.7 g (56%) of pure light yellow crystalline material. 
Other chemopreventive agents of the present inven 
tion can be synthesized using generally similar proce 
dures. In general, the synthesis procedures needed 
would be known to those skilled in the art. 
EXAMPLE 1 
Chemopreventive agents in accordance with the 
present invention have been tested for their ability to 
enhance the detoxification of the model electrophilic 
carcinogen 7r,8t-dihydroxy-9t, 10t-epoxy-7,8,9,10-tet 
rahydrobenzo(a)pyrene(BDPE-I). Assays were per 
formed both on an in vitro system and Chinese hamster 
ovary (CHO) cells. 
The assays were performed with seven analogs of 
6-MP. These included 6-MP substituted at the 2-posi 
tion with methyl-, hydroxyland thiosubstituent groups, 
9-methyl-6-MP, a thio-substituted imidazole, and 4-mer 
capto-1H-pyrazolo(3,4-d)pyrimidine (hereafter identi 
fied as thiopurinol.) Test chemicals were the highest 
purity available from either Aldrich (Milwaukee, Wis.) 
or Sigma (St. Louis, Mo.), and were used without fur 
ther purification. Unlabeled BPDE-I and (3H-BPDE-I 
were obtained from the NCI's Chemical Carcinogen 
Standard Repository. Stock solutions (32-500 uM) 














C. Concentrations and reactivity were verified by ab 
6 
sorbance and fluorescence spectrophotometry. Concen 
trated stock solutions of the thiol compounds to be 
tested were prepared in 0.1N NaOH. 
To directly measure the ability to enhance the detoxi 
fication of BPDE-I, aqueous reaction mixtures contain 
ing 5uM BPDE-I and 15-60 uM test compound in a 
supporting solvent containing 50 mM Tris pH 7.5 were 
monitored spectrophotometrically at 352 nm. Forma 
tion of adducts between the carcinogen and the thiol 
results in an increase in absorbance at 352 nm. This 
reaction is pseudo-first order, and the observed rate 
constant at any concentration of thiol can be obtained 
by curve-fitting. The observed rate constant increases 
linearly with concentration of thiol at low concentra 
tions, and the slope of this line, kcat, is a measure of the 
test compound's ability to detoxify the BPDE-I. These 
results are given in table 1 below. By this assay, 9-meth 
yl-6-MP is similar to 6-MP in catalysis of detoxification, 
and 2-methyl-6-MP and thiopurinol have significant 
activity. 
A more relevant test depends on the ability of BPDE 
I to bind covalently to DNA in vitro. Addition of in 
creasing amounts of thiol test compounds to reaction 
mixtures containing constant amounts of 3H-BPDE-I 
(1.6 uM) and purified DNA (45 ug/mL) inhibits the 
covalent binding of BPDE-I to the DNA. When this 
inhibition is expressed as a reciprocal (adduct level in 
the absence of test compound/adduct level in the pres 
ence of test compound) a linear relation is obtained, in 
which the slope of the line is a measure of the ability of 
the compound to compete with DNA for binding of the 
electrophilic carcinogen. In Table 1, this measure 
(kcat/kDNA) has been tabulated for each of the 6 com 
pounds tested. It can be seen that 3 compounds (9-meth 
yl-6-MP, 2,6-dithiopurine and thiopurinol) have activi 
ties comparable to or higher than 6-MP, while 2-OH-6- 
MP and 2-methyl-6-MP also have significant activity. 
Direct tests of the ability of the compounds to block 
the deleterious effects of the carcinogen in intact, nam 
malian cells were carried out. Cultures of AT3-2 cells, a 
subline of CHO cells, were maintained, treated with 1.0 
uM BPDE-I for 60 minutes, and analyzed for covalent 
binding to DNA as previously described by MacLeod 
et al (1987) Chem.-Biol. lnteract. 63:279-289, which is 
incorporated herein by reference. 
BPDE-I binds covalently to cellular DNA when 
added to the culture medium of CHO cells. The inhibi 
tion of this binding by the addition of thiopurines at a 
final concentration of either 12 M or 120 LM was 
tested, and the results are shown in table 1 below. Four 
of the compounds tested (9-methyl-6-MP, 2,6-dithiopu 
rine, thiopurinol, and 2-methyl-6-MP) exhibited activity 
comparable to or higher than 6-MP in the CHO cell 
assay. The remaining compounds showed lower but still 
significant activity. Other thiol-containing compounds 
with structures unrelated to 6-MP, specifically 2-mer 
captoethanol and mercaptoethanesulfonic acid, were 
ineffective in this assay. 
TABLE 1 
inhibition 
kcat Inhibition of of Cellular 
(X 10, DNA binding DNA binding at: 
Compound M-sec 1) (kcat/kDNA) 12 HM 120 M 
9-methyl-6-MP 1.83 2.82 67.6% 95.3% 
2,6-dithio-purine n.d. 0.773 61.6 94.7 
thiopurinol 0.64 1.096 43.4 89.6 
6-MP 1.78 0.89 n.d. 8.7 




kcat Inhibition of of Cellular 
(x10; DNA binding DNA binding at 
Compound M-sect) (cat/DNA) 12 uM 120 M 
2-OH-6-MP 0.31 0.427 2.6 76.7 
2-C-6-MP n.d 0.145 5.0 56.4 
MNI n.d. 0.66 4.7 31.8 
MNTI is l-methyl-4-nitro-5-thio-imidazole. 
Not deterinited. 
These tests showed that chemopreventive agents of 
the present invention will enhance the detoxification of 
BPDE-I and facilely form a chemical adduct with it. 
Such agents were further found to inhibit the binding of 
BPDE-I to DNA in Chinese hamster ovary cells (CHO 
cells) exposed to both compounds. This effect is the 
basis for the postulated activity in the chemoprevention 
of carcinogenesis. Inhibition of BPDE-I binding to 
DNA in CHO cells occurs at concentrations of 
chemopreventive agent which also inhibit the induction 
of mutations at the adenosine phosphoribosyl transfer 
ase locus in the same cells. 
The parent compound, 6-MP, has demonstrated fac 
ile reaction with BPDE-I over a wide pH range (6-10) 
and a wide temperature range (15-50° C.). 
EXAMPLE 2 
The effect of the present invention on tumorigenesis 
was tested as follows. Each experimental group con 
tained 30 female SENCAR mice. A solvent (0.2 mL) 
consisting of 75% tetrahydrofuran:24.9% dimethylsul 
foxide:0.1% triethylamine was applied topically to the 
shaven backs of the nice containing either no test com 
pound (control) or 1.0 or 10.0 amol of either 2,6-dithi 
opurine or thiopurinol. Fifteen minutes later, an initiat 
ing dose of BPDE-I (200 nmol in 0.2 mL tetrahydrofu 
ran) was applied to the same area. After 2 weeks, twice 
weekly application of the tumor promoter TPA was 
begun and carried out for 23 weeks. The appearance of 
skin tumors (papillomas) on the backs of the treated 
mice was recorded weekly for the duration of the ex 
periment. In these experiments, the incidence of skin 
tumors is very low in mice which do not receive the 
initiating BPDE treatment. 
In the control animals receiving solvent only, fol 
lowed by the initiating carcinogen, skin tumors began to 
appear after 6-8 weeks of promotion; the average num 
ber of tumors/mouse increased in a linear fashion 
throughout the first 20 weeks of promotion, and then 
began to level out at between 5 and 6 tumors per animal. 
This is the behavior expected from previous studies 
with this tumor model. In the animals treated with 2,6- 
dithiopurine (DTP), there was a clear, dose-dependent 
decrease in the tumor incidence. At the higher dose, 
there was about a 90% decrease in tumor incidence. 
Even at a 10-fold lower dose there was greater than 
50% inhibition of tumorigenesis. (See FIG. 1.) Thi 
opurinol also caused a dose-dependent inhibition of 
tumor formation; at week 28 the low dose TP group had 
24% fewer tumors than the control group and the high 
dose TP had 58% fewer tumors. (See FIG. 2.) Thus 
both compounds were capable of significant inhibition 
of tumor formation. Chemopreventive agents in accor 
dance with the present invention can suitably be formu 
lated as a composition including an effective amount of 
one or more of the active agents, and a pharmaceuti 
cally acceptable excipient, diluent, or carrier. Composi 














contain between about 0.001% and about 99% by 
weight active agents, preferably between about 0.001% 
and about 10%. 
Methods in accordance with the present invention 
comprise administering to an animal an effective 
amount of the compounds or compositions described 
above. The administering step is preferably by oral 
dosage, but can also suitably be parenteral and by intra 
venous, intraarterial, intramuscular, intralymphatic, 
intraperitoneal, subcutaneous, intrapleural, or intrathe 
cal injection, or by topical application. Suitable dosages 
are believed to be in the range of 0.01-100 mg/kg body 
weight, preferably between 0.1-50 mg/kg. 
A nontoxic 6-MP analog could be used as a chronic 
treatment (e.g. as a dietary supplement) to prevent the 
initiation of a carcinogenesis by electrophilic carcino 
gens. This could be in the population as a whole, or in 
selected high risk populations (e.g. roofers, coke oven 
workers, cancer patients exposed to electrophiles dur 
ing chemotherapeutic treatments, or persons with ge 
netically determined high cancer risks). An additional 
possible commercial use would be as an adjunct, protec 
tive therapy in cases where the therapeutic value of 
another drug is limited by side effects due to metabolism 
of that drug to an electrophilic form. Thus, in some 
cases the 6-MP analog might block the side effects with 
out blocking the therapeutic effect. 
The description and examples given in this patent are 
intended to illustrate the present invention. They are 
not intended to be an exhaustive list of all possible spe 
cific embodiments of the present invention. Those 
skilled in the art will recognize that modifications could 
be made to the specific embodiments listed here which 
would still be within the scope of the present invention. 
I claim: 
1. A method of detoxifying electrophilic toxicants, 
comprising administering to an animal an amount effec 
tive to detoxify an electrophilic toxicant of a compound 
having a low level of cytotoxicity, said compound being 
a substrate for an endogenous cellular transport system, 
said compound being selected from the group consist 







and a compound having the formula 
X1 
OTO N 
-N / N N 
X3 
where one of X1, X2, and X3 is a thiol. having 0-10 
carbons; another one of X1, X2, and X3 is selected from 
the group consisting of a halogen, a thiol having 0-10 
carbons, an aliphatic and an aromatic hydrocarbon 
having 1-18 carbons, and OR, where R is selected 
from the group consisting of H and an aliphatic and an 
5, 120,753 
aromatic hydrocarbon having 1-18 carbons; and the 
remaining one of X1, X2, and X is selected from the 
group consisting of H, a halogen, a thiol having 0-10 
carbons, an aliphatic and an aromatic hydrocarbon 
having 1-18 carbons, or OR2, where R2 is selected from 5 
the group consisting of H and an aliphatic and an aro 
matic hydrocarbon having 1-18 carbons. 
2. The method of claim 1, where one of X1, X2, and 
X is a thiol having 0-4 carbons; another one of X, X2, 
and X3 is selected from the group consisting of halo 
gens, thiols having 0-4 carbons, aliphatic and aromatic 
hydrocarbons having from 1-6carbons, and OR1, where 
R1 is selected from the group consisting of H and an 
aliphatic and an aromatic hydrocarbon having 1-6 car 
bons; and the remaining one of X1, X2, and X3 is se 
lected from the group consisting of H, a halogen, a thiol 
having 0-4 carbons, an aliphatic and an aromatic hydro 
carbon having 1-6 carbons, and OR2, where R2 is se 
lected from the group consisting of H and an aliphatic 
and an aromatic hydrocarbon having 1-6 carbons. 
3. A method of detoxifying electrophilic toxicants, 
comprising administering to an animal an amount effec 
tive to detoxify an electrophilic toxicant of a compound 
having a low level of cytotoxicity, said compound being 
a substrate for an endogenous cellular transport system, 












where X* is a thiol having 0-10 carbons; X5 and X6 are 
independently selected from the group consisting of H, 
a halogen, a thiol having 0-10 carbons, an aliphatic and 
an aromatic hydrocarbon having 1-18 carbons, and 
OR1, where R1 is selected from the group consisting of 40 
H and an aliphatic and an aromatic hydrocarbon having 
1-18 carbons; with the limitation that only one of X5 
and X6 can be H. 
4. The method of claim 3, where X is SH. 
5. The method of claim 3, where X5 and X6 are inde 
pendently selected from the group consisting of H, 
halogens, thiols having 0-4 carbons, aliphatic and aro 
matic hydrocarbons having 1-6 carbons, and OR 
where R is selected from the group consisting of H and 
an aliphatic and an aromatic hydrocarbon having 1-6 
carbons; with the limitation that only one of X5 and X6 
can be H. 
6. The method of claim 3, where x is SH, and where 
X5 and X6 are independently selected from the group 
consisting of H, a halogen, a thiol having 0-4 carbons, 
an aliphatic and an aroamtic hydrocarbon having 1-6 
carbons, and OR is selected from the group consisting 
of H and aliphatic and aromatic hydrocarbons having 
1-6 carbons; with the limitation that only one of X and 






7. A method of detoxifying electrophilic toxicants, 
comprising administering to an animal an amount effec 
tive to detoxify an electrophilic toxicant of a compound 
having a low level of cytotoxicity, said compound being 
a substrate for an endogenous cellular transport system, 





where X4 is a thiol having 0-4 carbons; X is selected 
from the group consisting of H, a thiol, having 0-4 
carbons, hydroxy, and an alkyl having 1-6 carbons, and 
X6 is selected from the group consisting of H and an 
alkyl having 1-6 carbons; with the limitation that only 
one of X5 and X6 can be H. 
8. The method of claim 7, where X is SH, X5 is se 
lected from the group consisting of H, SH, hydroxyl, 
and methyl; and X6 is selected from the group consisting 
of H, SH, and methyl; with the limitation that only one 
of X5 and X6 can be H. 
9. A method of detoxifying electrophilic toxicants, 
comprising administering to an animal an amount effec 
tive to detoxify an electrophilic toxicant of a composi 
tion which includes a compound having a low level of 
cytotoxicity, said compound being a substrate for an 
endogenous cellular transport system, said compound 
being selected from the group consisting of 9-methyl-6- 
mercaptopurine, 2,6-dithio-purine, and thiopurinol. 
10. A method of detoxifying mixtures of toxicants, in 
which polycyclic aromatic hydrocarbons are a major 
component in vivo in a mammal, comprising adminis 
tering to an animal an amount effective to detoxify an a 
toxicant in which polycyclic aromatic hydrocarbons 
are a major component of a compound having a low 
level of cytotoxicity, said compound being a substrate 
for an endogenous cellular transport system, said com 
pound having the formula 
X4 
O6) --, - 
X6 
where X is a thiol having 0-10 carbons; X5 and X6 are 
independently selected from the group consisting of H, 
a halogen, a thiol having 0-10 carbons, aliphatic and 
aromatic hydrocarbons having 1-18 carbons, and OR, 
where R is selected from the group consisting of H and 
an aliphatic and an aromatic hydrocarbon having 1-18 
carbons; with the limitation that only one of X5 and X6 
can be H. 
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